Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics, Inc. (BEAM)
NASDAQ:BEAM
BEAM Stock Chart & Stats
$28.93
-$0.69(-2.55%)
At close: 4:00 PM EST
$28.93
-$0.69(-2.55%)
Day’s Range― - ―
52-Week Range$13.53 - $35.25
Previous CloseN/A
Volume491.48K
Average Volume (3M)1.40M
Market Cap
$2.94B
Enterprise Value$1.57B
Total Cash (Recent Filing)$1.07B
Total Debt (Recent Filing)$151.42M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Mar 03, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding101,474,945
10 Day Avg. Volume1,097,651
30 Day Avg. Volume1,403,535
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.78
Price to Sales (P/S)32.14
P/FCF Ratio-5.73
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue28.11
Enterprise Value/Gross Profit-4.40
Enterprise Value/Ebitda-3.64
Forecast
1Y Price Target
$41.92Price Target Upside44.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityBEAM‑101 and risto‑cel demonstrate consistent trait‑like hemoglobin correction with durable fetal hemoglobin induction and no post‑treatment vaso‑occlusive crises reported, supporting potential curative impact for sickle cell patients.
Manufacturing Scalability And Operational EfficiencyOptimized ex vivo manufacturing with a short, reproducible vein‑to‑vein process and fewer mobilization cycles indicates scalable production that could lower treatment barriers and support commercial rollout.
Pipeline Diversification And Platform ValidationProgress across BEAM‑302, BEAM‑103 and ESCAPE, together with strategic collaborations, underscores platform breadth and positions the company to address both in vivo correction and safer conditioning markets.
Bears Say
Clinical Adoption And Safety UncertaintyReports of higher platelet transfusion rates in some datasets and uncertainty whether M‑AAT expression will meet therapeutic adoption thresholds create clinical and commercialization risk for liver‑targeted programs.
Competitive Pressure From Alternative TechnologiesThe rise of safer in vivo gene editors and ongoing weaknesses in some incumbent therapies increase competitive pressure, potentially constraining market share for ex vivo base‑editing treatments.
Investor Sentiment And Market Adoption RiskInvestor interest in the sickle cell program is muted amid faster clinical uptake of competing CRISPR approaches, which could limit enthusiasm and valuation support for ex vivo base‑editing assets.
Beam Therapeutics News
BEAM FAQ
What was Beam Therapeutics, Inc.’s price range in the past 12 months?
Beam Therapeutics, Inc. lowest stock price was $13.53 and its highest was $35.25 in the past 12 months.
What is Beam Therapeutics, Inc.’s market cap?
Beam Therapeutics, Inc.’s market cap is $2.94B.
When is Beam Therapeutics, Inc.’s upcoming earnings report date?
Beam Therapeutics, Inc.’s upcoming earnings report date is Mar 03, 2026 which is in 53 days.
How were Beam Therapeutics, Inc.’s earnings last quarter?
Beam Therapeutics, Inc. released its earnings results on Nov 04, 2025. The company reported -$1.1 earnings per share for the quarter, missing the consensus estimate of -$1.038 by -$0.062.
Is Beam Therapeutics, Inc. overvalued?
According to Wall Street analysts Beam Therapeutics, Inc.’s price is currently Undervalued.
Does Beam Therapeutics, Inc. pay dividends?
Beam Therapeutics, Inc. pays a Quarterly dividend of $0.225 which represents an annual dividend yield of N/A. See more information on Beam Therapeutics, Inc. dividends here
What is Beam Therapeutics, Inc.’s EPS estimate?
Beam Therapeutics, Inc.’s EPS estimate is -1.01.
How many shares outstanding does Beam Therapeutics, Inc. have?
Beam Therapeutics, Inc. has 101,474,945 shares outstanding.
What happened to Beam Therapeutics, Inc.’s price movement after its last earnings report?
Beam Therapeutics, Inc. reported an EPS of -$1.1 in its last earnings report, missing expectations of -$1.038. Following the earnings report the stock price went down -6.227%.
Which hedge fund is a major shareholder of Beam Therapeutics, Inc.?
Currently, no hedge funds are holding shares in BEAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beam Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.92 (44.90% Upside)
$41.92 (44.90% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.47%
12-Months-Change
Fundamentals
Return on Equity
-47.19%
Trailing 12-Months
Asset Growth
11.93%
Trailing 12-Months
Company Description
Beam Therapeutics, Inc.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
BEAM Stock 12 Month Forecast
Average Price Target
$41.92
▲(44.90% Upside)
Technical Analysis
Denali Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Immunocore Holdings
―
Ownership Overview
Currently, No data available
---